Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Macitentan in inoperable chronic thromboembolic pulmonary hypertension (CTEPH)
2013-002950-56Phase 2Completed
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Jan 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chronic thromboembolic pulmonary hypertension (CTEPH) comparing Macitentan 10 mg with Placebo (2 arms). Primary endpoint: Pulmonary vascular resistance at rest at Week 16. Started Jan 2014; status: completed.
02
Drugs
macitentan
03
Conditions
chronic thromboembolic pulmonary hypertension (CTEPH)
Beyond the preview
Go deeper on 2013-002950-56.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002950-56.